Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Consulting agrmnt CC transcript Director departure Inv. presentation
|
Orexigen Therapeutics, Inc. (OREXQ)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/04/2019 |
4
| BAUPOST GROUP LLC/MA (10% Owner) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Disposed of options to buy
@ $0 Disposed of 5,000,000 options to buy
@ $0 Disposed of 100,000,000 options to buy
@ $0 |
|
10/31/2018 |
4
| BAUPOST GROUP LLC/MA (10% Owner) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Sold 650,000 shares
@ $0.01, valued at
$6.5k
Sold 896,339 shares
@ $0.01, valued at
$9k
|
|
10/26/2018 |
4
| BAUPOST GROUP LLC/MA (10% Owner) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Sold 28,000 shares
@ $0.01, valued at
$280 Sold 652,500 shares
@ $0.01, valued at
$6.5k
|
|
04/26/2018 |
4
| BAUPOST GROUP LLC/MA (10% Owner) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Disposed of 16,483,517 options to buy
@ $7.5, valued at
$123.6M
|
|
03/16/2018 |
4
| Moglia Stephen A. (VP & Chief Accounting Officer) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Sold 1,694 shares
@ $0.24, valued at
$406.6 |
|
10/17/2017 |
4
| Lynch Thomas P. (EVP, Chief Admin Off, GC & Sec) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 69,600 restricted stock units
@ $0 |
|
10/17/2017 |
4
| Keyes Jason A (EVP, CFO) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 69,600 restricted stock units
@ $0 |
|
10/17/2017 |
4
| Flynn Peter D (EVP, Head of Global Dev) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 69,600 restricted stock units
@ $0 |
|
10/17/2017 |
4
| Cannell Thomas R (EVP, COO, Pres Global Com Prod) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 91,200 restricted stock units
@ $0 |
|
10/17/2017 |
4
| NARACHI MICHAEL (CEO & President) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 252,000 restricted stock units
@ $0 |
|
07/18/2017 |
4
| Zoth Lota S. (Director) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 5,000 options to buy
@ $2.88, valued at
$14.4k
|
|
07/18/2017 |
4
| MAHAFFY PATRICK J (Director) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 5,000 options to buy
@ $2.88, valued at
$14.4k
|
|
07/18/2017 |
4
| JORN DEBORA (Director) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 5,000 options to buy
@ $2.88, valued at
$14.4k
|
|
07/18/2017 |
4
| Honig Peter (Director) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 5,000 options to buy
@ $2.88, valued at
$14.4k
|
|
07/18/2017 |
4
| Endicott David J. (Director) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 5,000 options to buy
@ $2.88, valued at
$14.4k
|
|
07/18/2017 |
4
| BOCK LOUIS C (Director) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 5,000 options to buy
@ $2.88, valued at
$14.4k
|
|
07/18/2017 |
4
| DOVEY BRIAN H (Director) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 5,000 options to buy
@ $2.88, valued at
$14.4k
|
|
06/02/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/02/2017 |
4
| Lynch Thomas P. (EVP. General Counsel & Sec.) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 1,704 shares
@ $1.55, valued at
$2.6k
|
|
06/02/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/02/2017 |
4
| Cannell Thomas R (EVP, COO, Pres Global Com Prod) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 2,119 shares
@ $1.55, valued at
$3.3k
|
|
02/07/2017 |
4
| NARACHI MICHAEL (CEO & President) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 315,000 options
@ $4.1, valued at
$1.3M
Granted 157,500 options
@ $15, valued at
$2.4M
|
|
02/07/2017 |
4
| Lynch Thomas P. (EVP. General Counsel & Sec.) has filed a Form 4 on Orexigen Therapeutics, Inc. |
02/07/2017 |
4
| Keyes Jason A (SVP, CFO) has filed a Form 4 on Orexigen Therapeutics, Inc. |
02/07/2017 |
4
| Flynn Peter D (SVP, Dev, Reg Affairs, Safety) has filed a Form 4 on Orexigen Therapeutics, Inc. |
02/07/2017 |
4
| Cannell Thomas R (EVP, COO, Pres Global Com Prod) has filed a Form 4 on Orexigen Therapeutics, Inc. |
12/21/2016 |
4
| Moglia Stephen A. (VP, Chief Accounting Officer) has filed a Form 4 on Orexigen Therapeutics, Inc. |
12/02/2016 |
4
| NARACHI MICHAEL (CEO & President) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 802 shares
@ $1.67, valued at
$1.3k
|
|
12/02/2016 |
4
| Keyes Jason A (SVP, CFO) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 291 shares
@ $1.67, valued at
$486 |
|
12/02/2016 |
4
| Cannell Thomas R (EVP, COO, Pres Global Com Prod) has filed a Form 4 on Orexigen Therapeutics, Inc. |
07/14/2016 |
4
| Lynch Thomas P. (EVP. General Counsel & Sec.) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 131,250 options
@ $4.02, valued at
$527.6k
Granted 26,250 options
@ $4.02, valued at
$105.5k
Granted 78,750 options
@ $15, valued at
$1.2M
Granted 15,750 options
@ $15, valued at
$236.3k
|
|
07/14/2016 |
4
| Keyes Jason A (SVP, CFO) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 131,250 options
@ $4.02, valued at
$527.6k
Granted 26,250 options
@ $4.02, valued at
$105.5k
Granted 78,750 options
@ $15, valued at
$1.2M
Granted 15,750 options
@ $15, valued at
$236.3k
|
|
07/14/2016 |
4
| Flynn Peter D (SVP, Dev, Reg Affairs, Safety) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 131,250 options
@ $4.02, valued at
$527.6k
Granted 26,250 options
@ $4.02, valued at
$105.5k
Granted 78,750 options
@ $15, valued at
$1.2M
Granted 15,750 options
@ $15, valued at
$236.3k
|
|
07/14/2016 |
4
| Cannell Thomas R (EVP, Chief Commercial Officer) has filed a Form 4 on Orexigen Therapeutics, Inc.
Txns:
| Granted 157,500 options
@ $15, valued at
$2.4M
Granted 31,500 options
@ $15, valued at
$472.5k
Granted 262,500 options
@ $4.02, valued at
$1.1M
Granted 52,500 options
@ $4.02, valued at
$211.1k
|
|
|
|
|